Image courtesy: Getty / Futurism
The active ingredients in Ozempic and Wegoby have once again been proven to have health benefits beyond weight loss, with a large-scale analysis linking them to a reduced risk of Alzheimer’s disease.
Researchers at Case Western Reserve School of Medicine examined more than 1 million patient records and found that older adults with diabetes who took semaglutide had lower rates of Alzheimer’s disease than those taking other diabetes drugs. They found that they were much less likely to develop the disease.
This effect was most pronounced when comparing semaglutide to old-fashioned injectable diabetes insulin, with patients receiving semaglutide showing a whopping 70% lower risk of Alzheimer’s disease.
In the study, published in the journal Alzheimer’s and Dementia, Case Western researchers led by biomedical informatics expert Rong We conducted a randomized statistical analysis that mimicked the
Specifically, the CWR team looked at three years of medical data from people who had just started taking diabetes medications, including insulin, Ozempic, and the GLP-1 drug liraglutide, sold under the brand names Victoza. Their goal is to see how well they’re doing over time and see if there’s a link between diabetes treatment and cognitive health outcomes.
In an interview with NBC about the study results, Xu said he was surprised that semaglutide showed better efficacy than liraglutide, which has also been linked to slowing the progression of Alzheimer’s disease in another recent study.
It is worth noting that all participants in this study were prescribed Ozempic, whose dosage is up to 2 milligrams per weekly injection, whereas its weight loss sister drug, Wigovy, can be prescribed at a slightly higher dose of 2.4 milligrams. .
“Would we see even stronger effects if we had a higher-dose dosage form?” Xu wondered.
As stated in the study’s introduction, clinical trials specifically examining whether semaglutide has a preventive effect on Alzheimer’s disease have not yet been completed, but Novo Nordisk, the maker of Ozempic and Wigovy, is currently in a third trial. Stage clinical trials are underway. Exactly the subject.
“Our results indicate that further research on the use of semaglutide needs to be further investigated through randomized clinical trials,” Professor Xu said in a school press release, “therefore, it “Alternative drugs can be tested as potential treatments.”
From potential prevention of Alzheimer’s disease to lowering the urge to drink and smoke, these drugs have proven time and time again to be game-changers for the pharmaceutical industry, but the exact mechanism behind this is unclear. , remains very elusive as always.
More about GLP-1: Study finds Ozempic may be used to treat alcohol and drug addiction
